AxoGen, Inc. - $AXGN STOCK NEWS

Axogen, a leader in surgical solutions for peripheral nerve injuries, announced its participation in the Leerink Partners Healthcare Crossroads Conference.

CEO Karen Zaderej will engage in a fireside chat on May 29, 2024, at 3:40 p.m. CT / 4:40 p.m. ET in Austin, TX.

The event will be webcast live and later archived for 90 days on the company's Investors page.

Axogen, Inc. reported a 12.9% increase in revenue in the first quarter of 2024, reaching $41.4 million. The company's gross margin improved to 78.8%, while net loss decreased to $6.6 million. Adjusted net loss was $2.7 million, with adjusted EBITDA at $1.0 million. Cash, cash equivalents, and investments totaled $23.6 million. Axogen is focusing on reaching profitability, with upcoming product launches and submission milestones.

Axogen, Inc. (NASDAQ: AXGN) announces the first surgical implants of its Avive+ Soft Tissue Matrix™, a resorbable barrier for nerve injuries. The product aims to enhance nerve protection during healing phases. Surgeon feedback is positive, with a national launch expected in Q2 2024. Avive+ is a placenta-based allograft processed under FDA regulations to address various nerve injuries and defects, offering promising solutions for patients experiencing nerve trauma.

Axogen, Inc. will report its first quarter 2024 financial results on May 2, 2024, followed by an investment-community conference call and webcast. Investors can participate via phone or webcast.

Axogen, Inc. (AXGN) reports strong financial results for Q4 2023 and full-year 2023 with revenue growth, net loss reduction, and new product launches. The company's revenue increased to $42.9 million in Q4, representing an 18.7% growth from 2022. Full-year revenue reached $159.0 million, a 14.7% increase from 2022. Axogen aims for further growth with the launch of Avive+ Soft Tissue Matrix in Q2 2024 and expects revenue between $177 million to $181 million for 2024.

Axogen, Inc. (NASDAQ: AXGN) will report its 2023 fourth quarter and full-year financial results on March 5, 2024. The company specializes in innovative surgical solutions for peripheral nerve injuries.

Axogen, Inc. (NASDAQ: AXGN) announced the induction of John Manning as the Area Vice President of Sales and the granting of equity awards as an inducement for his employment. The equity grant consists of non-qualified stock options to purchase 18,700 shares of the company’s common stock and non-qualified restricted stock units representing 10,000 shares of the company’s common stock. The stock options have an exercise price of $9.75 per share and will vest over a four-year period, while the RSUs are subject to vesting over 4 years.

Axogen, Inc. (AXGN) announced positive results from its REPOSE clinical study, demonstrating the statistical superiority of Axoguard Nerve Cap over standard-of-care neurectomy in reducing pain for patients with symptomatic neuroma. The study met its primary endpoint for pain reduction, with the Axoguard Nerve Cap group showing superior results compared to the standard-of-care neurectomy group over the 12-month follow-up period.

Axogen, a global leader in surgical solutions for peripheral nerve injuries, announced preliminary unaudited fourth quarter and full-year 2023 revenue. Fourth-quarter revenue is expected to be $42.7 million, representing an 18% increase over 2022. Full-year 2023 revenue is expected to be $158.8 million, a 15% increase over 2022. Core Accounts are expected to represent 65% of revenue for 2023, with 375 accounts at the end of the fourth quarter. The company achieved a milestone of surpassing 100,000 Avance Nerve Graft implants since its launch. Axogen also introduced Axoguard HA+ Nerve Protector and plans to roll out Avive+ Soft Tissue Matrix in 2024. The company expects to be cash flow positive and profitable in 2024.